These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bayer's venerable testosterone replacement ... The group is facing the threat of competition from big-selling pharma products Eylea (aflibercept) for ophthalmic diseases and anticoagulant Xarelto ...

LEO Pharma will acquire the global product rights, except for Afghanistan and Pakistan, and take over the sales and marketing teams in 14 countries, as well as Bayer’s Italian factory in Segrate.

Bayer pharma chief sees no big acquisitions in near ... of some long-running mass tort litigation based on traditional product liability theories of toxic exposure, and potentially the rise ...

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its ...

Meanwhile, Bayer's Pharmaceutical division has delivered ... This growth was driven by significant gains from new products, with Nubeqa and Kerendia achieving growth rates of 83.2% and 96.4% ...

“Rather than a lumbering corporation, Bayer will emerge as agile ... Another example: the company’s pharma division, based in Italy, has cut product release times by 50%.

However, new pharma products, including prostate cancer therapy Nubeqa and kidney disease therapy Kerendia, powered Bayer's ...

Ein Jahr später sagte er nun, Bayer strebe keine Pharma- und Biotech-Deals an, deren Volumen zum oberen Rand dieser Spanne hin gehe. Priorität habe stattdessen die Senkung der Schuldenlast.

Leaps by Bayer announces one of the largest global surveys of society’s attitudes toward breakthrough technologies: Berlin, Germany Tuesday, January 21, 2025, 12:00 Hrs [IST] As ...

Bayer's pharmaceuticals medical director, Dr Naren Jairam, said after consulting with the South African Health Products Authority (Sahpra) they had decided to initiate a Class II, Type A recall ...